NextCure (NASDAQ:NXTC) Shares Up 6.7% – Still a Buy?

NextCure, Inc. (NASDAQ:NXTC) was up 6.7% during trading on Monday . The company traded as high as $0.54 and last traded at $0.53. Approximately 286,624 shares changed hands during trading, an increase of 167% from the average daily volume of 107,261 shares. The stock had previously closed at $0.50.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of NextCure in a report on Monday, March 17th.

NextCure Trading Up 6.7%

The firm has a 50-day simple moving average of $0.42 and a 200-day simple moving average of $0.68. The firm has a market cap of $14.82 million, a P/E ratio of -0.25 and a beta of 1.07.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. Research analysts predict that NextCure, Inc. will post -1.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Pfizer Inc boosted its stake in NextCure by 29.7% in the first quarter. Pfizer Inc now owns 1,891,763 shares of the company’s stock valued at $909,000 after acquiring an additional 433,213 shares in the last quarter. Tang Capital Management LLC lifted its holdings in shares of NextCure by 7.3% during the 4th quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock valued at $540,000 after purchasing an additional 47,614 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of NextCure by 27.9% in the 4th quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock worth $400,000 after purchasing an additional 113,300 shares in the last quarter. Peapod Lane Capital LLC purchased a new position in NextCure during the 4th quarter worth $311,000. Finally, Citadel Advisors LLC grew its stake in NextCure by 40.6% during the 4th quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock worth $61,000 after buying an additional 22,724 shares during the last quarter. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.